COVID cash funds a rocky oncology pivot
- BioNTech still makes most revenue from COMIRNATY, its COVID-19 vaccine with Pfizer.
- Management cut 2026 revenue guidance to €1.6 billion to €1.9 billion on weaker COVID-19 demand.
- The BMS deal for pumitamig brings $3.5 billion of noncontingent cash through 2028.
- Oncology now takes about 90% of current R&D spend, so trial results matter more than vaccine headlines.
- The company faces execution risk as new CEO Guido Oelkers prepares to take over by February 1.
A funded but hard pivot
The bull case is simple. BioNTech turned the COVID-19 vaccine boom into a massive funding base, ending 2025 with about €17.2 billion in cash and investments. That gives the company time to run large oncology trials, including a new Phase III trial for the prostate cancer drug elfetabart, without needing to raise money in a weak market.
The biggest new support is the Bristol Myers Squibb partnership for pumitamig, also called BNT327. BMS paid $1.5 billion upfront, and BioNTech expects $2.0 billion more in noncontingent anniversary payments through 2028. The two companies will share development, manufacturing, profits, and losses on a 50-50 basis.
The bear case is that having cash does not make drugs work. iNeST, the individualized mRNA cancer vaccine platform, missed its progression-free survival endpoint in advanced melanoma. The legacy COVID-19 business is also fading faster than expected, prompting a recent guidance cut. Further complicating matters, the FDA delayed the BLA submission for the lead cancer drug BNT323 into 2026 to review more data.
The setup is mixed, which matches Finn's cautious score. BioNTech has money, partners, and many shots on goal. It also faces falling COVID-19 revenue, execution risks in its pipeline, and a major leadership transition as Guido Oelkers prepares to replace the founding CEO.
Vaccine cash, cancer spend
BioNTech makes commercial money mainly from COMIRNATY, its COVID-19 vaccine sold with Pfizer. The vaccine market is now seasonal and smaller than during the pandemic, and management recently cut 2026 revenue guidance to between €1.6 billion and €1.9 billion. This cash cow is steadily declining.
The company is spending that vaccine cash on a multi-technology cancer pipeline. It started as an mRNA leader, but it now works heavily on bispecific antibodies and antibody-drug conjugates. Antibody-drug conjugates are targeted cancer drugs that link an antibody to a cell-killing payload, representing a massive portion of the current R&D budget.
The BMS deal changes the funding math. BioNTech recognized €613 million of out-licensing revenue in late 2025 from the pumitamig partnership, and expects $2.0 billion more in noncontingent payments through 2028. That helps bridge the gap as COVID-19 sales shrink.
The model breaks if late-stage cancer trials fail, regulators ask for more data, or manufacturing cannot scale. BioNTech reports as one operating segment, but economically the company is moving from one shrinking commercial vaccine product toward several still-unproven oncology products.
What BioNTech is betting on
COMIRNATY
COMIRNATY is the COVID-19 vaccine sold with Pfizer. It still funds much of the company, but 2026 guidance assumes significantly lower COVID-19 vaccine revenue.
Pumitamig, BNT327
Pumitamig is a PD-L1 and VEGF bispecific antibody. BioNTech shares global development and commercialization with BMS.
BNT323
BNT323 is a HER2 antibody-drug conjugate being prepared for a possible BLA in second-line endometrial cancer. The filing moved into 2026 after the FDA asked for more analysis.
Elfetabart, BNT324
Elfetabart is a B7-H3 antibody-drug conjugate. It recently entered a Phase III trial for metastatic castration-resistant prostate cancer.
iNeST
iNeST is BioNTech's individualized mRNA cancer vaccine platform. After missing in advanced melanoma, the strategy is focused more on adjuvant disease.
FixVac
FixVac is an off-the-shelf mRNA cancer vaccine approach. BNT111 met a Phase 2 primary endpoint in melanoma, but it still needs later proof before it can become a product.
One segment, three revenue buckets
BioNTech reports one operating and reporting segment. The mix shown here uses the fiscal 2025 revenue categories disclosed in the 2025 Form 20-F, as 2026 segment actuals remain pending.
What could go wrong
COVID revenue keeps shrinking
High impact · High oddsCOVID-19 vaccine demand is fading faster than expected. Management cut 2026 total revenue guidance to a range of €1.6 billion to €1.9 billion, citing weaker global demand and Germany using old inventory. If sales keep dropping, the cash bridge to oncology gets thinner.
iNeST works too slowly in advanced cancer
Medium impact · Medium oddsThe individualized mRNA vaccine iNeST missed its progression-free survival endpoint in advanced melanoma. BioNTech noted the immune response may take six to eight weeks to develop, which can be too slow for fast-growing metastatic disease. The platform may still work better after surgery, but that narrows the near-term market.
BNT323 faces FDA and supply risk
High impact · Medium oddsBioNTech planned a BLA for BNT323 in endometrial cancer, but the submission moved into 2026 after FDA discussions about additional data needs. The internal risk is bigger because manufacturing relies heavily on a China-based CDMO. A delay or supply problem could push out the first oncology launch.
Pumitamig must prove itself in Phase 3
High impact · Medium oddsThe BMS partnership brings large noncontingent cash, but pumitamig still has to succeed in broad Phase 3 testing. BioNTech and BMS are sharing costs, profits, and losses. The market may give little credit to this program until randomized data are clear.
Leadership handoff creates uncertainty
Medium impact · Medium oddsCo-founders Ugur Sahin and Ozlem Tureci are stepping away to start a new venture. The company named Guido Oelkers as the new CEO, taking over by February 1. The risk is that a hard oncology pivot loses momentum during a major transition at the top.
Legal and patent costs keep draining cash
Medium impact · Medium oddsBioNTech recorded large legal and settlement expenses in recent years for contractual and patent disputes. These costs do not decide whether the cancer drugs work, but they drain cash while revenue is falling. More disputes would make the transition period more expensive.
In one breath
Is BioNTech still mainly a COVID vaccine company?
Commercially, yes. Most recent revenue comes from COVID-19 vaccine sales. Strategically, the company is trying to become an oncology company, with about 90% of current R&D spend going to cancer drugs.
Why does the BMS deal matter for BioNTech?
The BMS deal helps pay for a much larger pumitamig trial program. It gives BioNTech $1.5 billion upfront and $2.0 billion in noncontingent anniversary payments through 2028, while sharing future costs and economics.
What is the next big BioNTech catalyst?
Investors should watch the 2026 BNT323 filing path, the Phase 3 prostate cancer trial for elfetabart, and randomized data from pumitamig studies. The handover to incoming CEO Guido Oelkers on February 1 is also a major event.
Does BioNTech have enough cash to fund the pivot?
BioNTech ended 2025 with about €17.2 billion in cash, cash equivalents, and security investments. That is a strong cushion, but it does not remove clinical, regulatory, or execution risk.
